|Target:||Quantity: Medicare rebates will be provided for an estimated 243 million services, representing approximately 11.6 services per capita.|
|Result:||Target met.||In 2005-06, Medicare Australia processed 247.4 million Medicare services, representing 12.0 services per capita.|
|Target:||Quantity: An estimated 690,000 families and 140,000 singles benefit from the extended Medicare safety net in calendar year 2005.|
|Result:||Target not met.||As at 30 June 2006, for services provided in 2005, 622,211 families and 117,595 singles have either received extended Medicare safety net (EMSN) benefits or will receive benefits when their out-of-pocket expenses have been substantiated. The numbers of families and singles benefiting from the EMSN will increase further as claims for the 2005 calendar year continue to be submitted to Medicare Australia for processing.|
|Target:||Quality: 100% of new medical services listed for funding under the MBS have been assessed for evidence of safety, efficacy and cost effectiveness.|
|Result:||Target met.||All new medical services were listed on the MBS following assessment by the Medical Services Advisory Committee.|
|Target:||Quantity: The number of breast cancer patients assisted through the Herceptin program is 750.|
|Result:||Target met.||Since the inception of the Herceptin Program 2,157 patients have received assistance.|
|Target:||Quantity: The average cost of Herceptin treatment for patients is $50,000.|
|Result:||Target not met.||
The most recent data shows the average course of treatment for patients in the Herceptin program is longer than originally forecast. The dosage of Herceptin relates principally to body weight and the average body weight of the patient group was slightly higher than expected; this, combined with the longer period of treatment, meant that the average cost of treatment for one year was approximately $67,000.
Note: This program operates outside the PBS, for patients with late-stage breast cancer. Herceptin was added to the PBS for patients with early-stage breast cancer in October 2006.
|Target:||Quantity: An estimated 184 million Pharmaceutical Benefits Scheme prescriptions will be subsidised for general and concessional patients, representing approximately 9.0 prescriptions per capita.|
|Result:||Decrease from previous year.||The number of prescriptions dispensed in 2005-06 subsidised under the PBS was 168 million. This compared with 170 million in 2004-05.|
|Target:||Quantity: An estimated 1.2 million families and singles qualify for reduced patient copayments under the PBS safety net.|
|Result:||Target not met.||Reaching the PBS safety net threshold is calculated over a calendar year. In the calendar year 2005, 1.14 million families and singles qualified for reduced patient copayments under the PBS safety net.|
|Target:||Efficiency: Growth in expenditure on the Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme (RPBS) is 8.6% for the year.|
|Result:||Script volumes were 1.1% lower than expected due to changes in patterns of prescribing and drug use.||Changes in patterns of prescribing and drug use and the impact of measures to reduce the cost to government of some medicines contributed to expenditure on the PBS and the RPBS for 2005-06 growing at a rate of 2.5%.|
|Target:||Quality: An estimated 779,000 persons with diabetes benefit from subsidised products and services through the National Diabetes Services Scheme.|
|Result:||Target met.||As at 30 June 2006, there were nearly 782,000 persons with diabetes registered on the National Diabetes Services Scheme (NDSS). Of those, an estimated 450,000 directly benefited from accessing subsidised products through the NDSS. The remaining 332,000 benefited from a range of NDSS educational and information services.|
|Target:||Quality: Ministers' satisfaction with the quality, relevance and timeliness of our advice for Australian Government decision making.|
|Result:||Target met.||Ministers were satisfied with the quality, relevance and timeliness of advice provided for Australian Government decision making.|
|Target:||Quality: Production of timely evidence-based policy research.|
|Result:||Target met.||Evidence-based policy research undertaken by the Department, such as the provision of policy advice to the Minister for the implementation of changes to the Medicare Benefits Schedule, was produced in a timely manner.|
|Target:||Quality: Administered budget predictions are met and actual expenses vary less than 0.5% from budgeted expenses.|
|Result:||Target met.||Actual expenses for Outcome 2 were $17.329 billion compared to a predicted 17.255 billion. Overall expenses varied by 0.43% from budgeted expenses.|
|Target:||Quality: Opportunity for stakeholders to participate in program development.|
|Result:||Target met.||The Fourth Community Pharmacy Agreement provides more than $500 million in funding for a range of professional pharmacy programs. A new consultative committee, the Professional Programs and Services Advisory Committee, was established in March 2006 to provide advice to the Minister on the funding of these programs. Membership includes the Pharmacy Guild of Australia and other members appointed by the Minister.
As well as development of new services, the Medicare Benefits Consultative Committee and the Optometric Benefits Consultative Committee have an ongoing role in the review of existing services to ensure that they reflect and encourage current clinical practice.
Review of the Visudyne Therapy program
|TimeFrame:||Commencement date: July 2005
End date: May 2006
Produced by the Portfolio Strategies Division, Australian Government Department of Health and Ageing.
If you would like to know more or give us your comments contact: firstname.lastname@example.org